- Home
- BIIB vs AER Comparison
BIIB vs AER Comparison
Compare BIIB & AER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- AER
- Stock Information
- Founded
- BIIB 1978
- AER 1995
- Country
- BIIB United States
- AER Ireland
- Employees
- BIIB N/A
- AER N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- AER Diversified Commercial Services
- Sector
- BIIB Health Care
- AER Consumer Discretionary
- Exchange
- BIIB Nasdaq
- AER Nasdaq
- Market Cap
- BIIB 18.7B
- AER 21.0B
- IPO Year
- BIIB 1991
- AER 2006
- Fundamental
- Price
- BIIB $132.22
- AER $123.77
- Analyst Decision
- BIIB Buy
- AER Strong Buy
- Analyst Count
- BIIB 27
- AER 7
- Target Price
- BIIB $188.09
- AER $122.57
- AVG Volume (30 Days)
- BIIB 1.4M
- AER 1.7M
- Earning Date
- BIIB 10-29-2025
- AER 07-30-2025
- Dividend Yield
- BIIB N/A
- AER 0.87%
- EPS Growth
- BIIB 31.67
- AER 1.32
- EPS
- BIIB 10.45
- AER 15.88
- Revenue
- BIIB $9,997,000,000.00
- AER $7,984,195,000.00
- Revenue This Year
- BIIB $2.00
- AER $1.51
- Revenue Next Year
- BIIB N/A
- AER $2.65
- P/E Ratio
- BIIB $12.64
- AER $7.80
- Revenue Growth
- BIIB 3.36
- AER 2.80
- 52 Week Low
- BIIB $110.04
- AER $85.57
- 52 Week High
- BIIB $206.70
- AER $124.48
- Technical
- Relative Strength Index (RSI)
- BIIB 46.86
- AER 76.60
- Support Level
- BIIB $135.22
- AER $112.05
- Resistance Level
- BIIB $138.50
- AER $114.10
- Average True Range (ATR)
- BIIB 3.37
- AER 1.93
- MACD
- BIIB -0.47
- AER 1.20
- Stochastic Oscillator
- BIIB 28.22
- AER 95.44
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About AER AerCap Holdings N.V.
AerCap Holdings NV is an aircraft leasing company. Its activities include leasing, financing, sales, and management of commercial aircraft and engines. It also provides aircraft asset management and corporate services to securitization vehicles, joint ventures, and other third parties.It has one business segment: leasing, financing, sales and management of commercial flight equipment (Commercial Flight Equipment Segment).Through its subsidiary, the group also provides engine leasing, certified aircraft engines, airframes, and engine parts. Its geographical segments include United Kingdom, United States, and Other countries.